I. Benedek

发表

Hepatic but not intestinal CYP3A4 displays dose‐dependent induction by efavirenz in humans

P. Watkins, S. Mouly, D. Kornhauser, 2002, Clinical pharmacology and therapeutics.

Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative.

R. Dai, L. Gan, Summer L Jolley, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.

S. Vosburg, S. Comer, J. Manubay, 2012, Drug and alcohol dependence.

Variability in the Pharmacokinetics and Pharmacodynamics of Low Dose Aspirin in Healthy Male Volunteers

H. Pieniaszek, D. Kornhauser, I. Benedek, 1995, Journal of clinical pharmacology.

The effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tablets.

W. Fiske, I. Benedek, Q. Xiang, 2012, The journal of pain : official journal of the American Pain Society.

Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects.

P. McNamara, R. Blouin, I. Benedek, 1984, British journal of clinical pharmacology.

Effect of Moricizine on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers

H. Pieniaszek, W. Schary, I. Benedek, 1992, Journal of clinical pharmacology.

Serum alpha 1-acid glycoprotein and the binding of drugs in obesity.

P. McNamara, R. Bell, R. Blouin, 1983, British journal of clinical pharmacology.

Dose-Dependent Pharmacokinetics of Warfarin in Healthy Volunteers

H. Pieniaszek, I. Benedek, S. P. King, 1995, Pharmaceutical Research.

Physiological model for distribution of sulfathiazole in swine.

T. Hayden, D. Bourne, W. Fiske, 1984, Journal of pharmaceutical sciences.

Altered drug-serum protein binding in the genetically obese Zucker rat.

P. McNamara, R. Blouin, I. Benedek, 1985, Journal of pharmaceutical sciences.

Influence of smoking on serum protein composition and the protein binding of drugs 1

P. McNamara, R. Blouin, I. Benedek, 1984, The Journal of pharmacy and pharmacology.

Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release

W. Fiske, I. Benedek, Q. Xiang, 2011, Drug design, development and therapy.

Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz).

J. Gao, M. Hussain, G. Digenis, 2007, Journal of pharmaceutical sciences.

Enzyme Induction by Moricizine: Time Course and Extent in Healthy Subjects

H. Pieniaszek, I. Benedek, A. Davidson, 1994, Journal of clinical pharmacology.

Pharmacokinetic Interactions of Moricizine and Diltiazem in Healthy Volunteers

H. Pieniaszek, W. Flamenbaum, I. Benedek, 1996, Journal of clinical pharmacology.

Dose Proportionality of Moricizine After Escalating Multiple Doses in Healthy Volunteers

I. Benedek, D. Garner, Henry J. Pieniaszek, 1991, Journal of clinical pharmacology.

Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.

R. Kapil, W. Fiske, I. Benedek, 2004, Clinical therapeutics.

(241) Bioavailability of oxymorphone extended-release tablets following consumption of alcohol or food

H. Ahdieh, W. Fiske, I. Benedek, 2008 .

Pharmacokinetic interaction between DMP 266 and nelfinavir mesylate in healthy volunteers

D. Kornhauser, J. L. Joseph, W. Fiske, 1997 .